Gilead Announces Generic Version Of Truvada Available In 2020, Will Donate Drug Used For PrEP To 200K U.S. Patients
NBC News: Generic HIV prevention drug coming in 2020, Gilead says
“Gilead Sciences announced Wednesday that a generic version of Truvada will be available in September 2020, one year earlier than expected. … While a month’s supply of generic Truvada is available in countries around the world for as little as $70, in the United States a month’s supply sells for $1,600 to $2,000, and activists have mounted a pressure campaign to force Gilead to make the drug more widely available in order to curb the global HIV epidemic…” (Fitzsimons, 5/8).
New York Times: Gilead Will Donate Truvada to U.S. for HIV Prevention
“Gilead Sciences, maker of Truvada, the only drug approved to prevent infection with HIV, will donate enough of the drug to supply 200,000 patients annually for up to 11 years, federal health officials announced on Thursday. … Gilead appears to be following a pattern set in 2001 by other drug companies. While millions of Africans died of AIDS because their drugs cost as much as $20,000 a year, drug makers refused to cut their overall prices. But the companies did offer to donate limited amounts of HIV medications — all while pressuring the United States and European governments to make sure that generic drugs made in India were kept out of the market. The tactic ultimately failed, and Indian companies now supply almost all of Africa’s HIV drugs. In Africa, generic Truvada is sold for about $60 a year. … Gilead will donate Truvada until [the generic] Descovy is approved for HIV prevention, then switch patients to the new drug… (McNeil, 5/9).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.